SCHEMBL217106

SCHEMBL217106

NC(=O)C1CCCCCCCCCCC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.58
CES1 P23141 1/20 0.58
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
ATM Q13315 1/20 0.52
CYP2D6 P10635 1/20 0.52
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
NOS2 P35228 2/20 0.48
EPHX1 P07099 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
HSD11B1 P28845 1/20 0.41
MAPK1 P28482 1/20 0.40
RECQL P46063 1/20 0.39
ALOX5 P09917 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216550 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
SCHEMBL28636550 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
SCHEMBL30542351 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
SCHEMBL30542352 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
SCHEMBL215922 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
SCHEMBL25485911 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
SCHEMBL217428 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
Cyclohexane Carboxamide SCHEMBL26181 1.00
SCHEMBL218387 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A
SCHEMBL27938035 1.00 CES2 (0.58) CES2CES1KDM4EMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452521-A1 TETRAHYDROINDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2019-03-13 EP claimed
WO-2017192226-A1 TETRAHYDROINDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2017-11-09 WO claimed
US-7041841-B1 Process for producing crystalline poly-α-olefins with a monocyclopentadienyl transition metal catalyst system EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-05-09 US claimed
US-6262197-B1 AS POLYMERIZATION CATALYST IN OLEFIN POLYMERIZATION TARGOR GMBH (DE) 2001-07-17 US claimed
US-5808122-A Organometallic compound HOECHST AKTIENGESELLSCHAFT (DE) 1998-09-15 US claimed
US-5726333-A POLYMERIZATION CATALYSTS HOECHST AG (DE) 1998-03-10 US claimed
US-20240084056-A1 Polyolefin-Based Ionomers and Production Thereof EXXONMOBIL CHEMICAL PATENTS INC (US) 2024-03-14 US disclosed
WO-2023250240-A1 LOW COST PROCESSES OF IN-SITU MAO SUPPORTATION AND THE DERIVED FINISHED POLYOLEFIN CATALYSTS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-12-28 WO disclosed
EP-4271718-A1 POLYOLEFIN-BASED IONOMERS AND PRODUCTION THEREOF ExxonMobil Chemical Patents Inc. (US) 2023-11-08 EP disclosed
US-11766669-B2 Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-09-26 US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-20230242745-A1 Process for Production of Thermoplastic Vulcanizates using Supported Catalyst Systems and Compositions Made Therefrom EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-08-03 US disclosed
WO-2022146634-A1 POLYOLEFIN-BASED IONOMERS AND PRODUCTION THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2022-07-07 WO disclosed
EP-0742225-A1 Organometallic compound HOECHST AKTIENGESELLSCHAFT (DE) 1996-11-13 EP disclosed
EP-0739897-A1 Polynuclear metallocene compound, process for preparing it and its use as catalyst HOECHST AKTIENGESELLSCHAFT (DE) 1996-10-30 EP disclosed
EP-0694557-A2 Organo metallic compounds HOECHST AKTIENGESELLSCHAFT (DE) 1996-01-31 EP disclosed
CN-1107162-A Metallocen method for preparation of same and application of same as catalyst HOECHST AG (DE) 1995-08-23 CN disclosed
EP-0654476-A1 Metallocenes, their preparation and use as catalysts HOECHST AKTIENGESELLSCHAFT (DE) 1995-05-24 EP disclosed
EP-0631589-A1 IONIC CATALYST FOR THE PRODUCTION OF POLY-$g(a)-OLEFINS OF CONTROLLED TACTICITY EXXON CHEMICAL PATENTS INC. (US) 1995-01-04 EP disclosed
WO-1993019103-A1 IONIC CATALYST FOR THE PRODUCTION OF POLY-α-OLEFINS OF CONTROLLED TACTICITY EXXON CHEMICAL PATENTS INC. (US) 1993-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CES2 1669/4885CES1 1136/4885KDM4E 190/4885
US-11766669-B2 Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof MLX, ZYX, TXN CES2 4035/4885CES1 3464/4885KDM4E 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.